Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

2012’s Top Biopharma Dealmakers

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca was the top in-licenser, snagging a $3.4 billion pact with BMS for Amylin’s diabetes assets, making metabolic diseases the leading therapeutic area in biopharma alliances.

You may also be interested in...



In 2012, Buyer’s Market Made Alliances Rarer

With little leverage against Big Pharma, some smaller companies are turning away from long-standing partnering strategies. It’s one reason dealmaking slowed considerably in 2012, part of a three-year trend that also highlights increasing reliance on heavily structured partnerships.

How Far Can Big Pharma Collaboration Go? Much Further, Executives Say

Big pharma collaborations and other new or once-rare models of business development can help companies ‘do more with less’, according to AstraZeneca’s and Merck’s heads of business development, who spoke at Elsevier’s Pharmaceutical Strategic Alliances conference.

The Biopharma A List: Taking The Pulse Of Newco Creation

The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

PS074776

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel